Canada· CA-DIN-02414295

ISTODAX

A romidepsin product containing romidepsin, registered in Canada by BRISTOL-MYERS SQUIBB CANADA. The same ATC class is registered in 2 of our 19 countries.

ATC L01XH02

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedISTODAXATCL01XH02REGISTER NO.CA-DIN-02414295PACKS LISTED0CHECKEDOctober 1, 2026

Where it is registered

Romidepsin is registered in 2 of 19 countries.

Countries holding a registration under ATC L01XH02 (romidepsin), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)

Romidepsin · ATC L01XH02

2 / 19 countries

  • Canada
  • Japan
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
ROMIDEPSIN
Manufacturer
BRISTOL-MYERS SQUIBB CANADA
Country
Canada (CA)
ATC code
L01XH02
ATC class
Romidepsin
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for romidepsin.

Graded by severity as the source publishes them — 96 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Romidepsin · interactions on record

434 records

  • 96 severe
  • 335 moderate
  • 3 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Romidepsin in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All romidepsin products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ea8bf138-359c-4a97-951c-a9705f01dd18
GET /v1/drugs/ea8bf138-359c-4a97-951c-a9705f01dd18?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "02414295",
  "form": "KIT",
  "class": "Human",
  "routes": [
    "INTRAVENOUS"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "L01XH02",
  "schedule": [
    "Prescription"
  ],
  "drug_code": "89895",
  "strengths": [
    "10 MG"
  ],
  "ahfs_class": null,
  "substances": [
    "ROMIDEPSIN"
  ],
  "product_categorization": null
}

See everything about romidepsin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.